ATE234354T1 - Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind. - Google Patents

Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind.

Info

Publication number
ATE234354T1
ATE234354T1 AT97947515T AT97947515T ATE234354T1 AT E234354 T1 ATE234354 T1 AT E234354T1 AT 97947515 T AT97947515 T AT 97947515T AT 97947515 T AT97947515 T AT 97947515T AT E234354 T1 ATE234354 T1 AT E234354T1
Authority
AT
Austria
Prior art keywords
insulin
composition
growth factor
cells treated
breast cancer
Prior art date
Application number
AT97947515T
Other languages
English (en)
Inventor
Walter C Low
Margaret A Wallenfriedman
Lan Chiang
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE234354T1 publication Critical patent/ATE234354T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97947515T 1996-11-22 1997-11-14 Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind. ATE234354T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/755,558 US6071891A (en) 1996-11-22 1996-11-22 Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
PCT/US1997/020815 WO1998022579A1 (en) 1996-11-22 1997-11-14 Insulin-like growth factor 1 receptor (igf-1r) antisense oligonucleotide-treated breast cancer cells composition

Publications (1)

Publication Number Publication Date
ATE234354T1 true ATE234354T1 (de) 2003-03-15

Family

ID=25039654

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97947515T ATE234354T1 (de) 1996-11-22 1997-11-14 Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind.

Country Status (7)

Country Link
US (1) US6071891A (de)
EP (1) EP0941317B1 (de)
JP (1) JP2001504487A (de)
AT (1) ATE234354T1 (de)
CA (1) CA2272824A1 (de)
DE (1) DE69719785T2 (de)
WO (1) WO1998022579A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900186B1 (en) * 1999-06-21 2005-05-31 Murdock Children's Research Institute Method for the prophylaxis and/or treatment of medical disorders
US7629323B2 (en) * 2003-01-21 2009-12-08 Northwestern University Manipulation of neuronal ion channels
WO2004072284A1 (en) * 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
ES2527871T3 (es) * 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
EP2385053B1 (de) * 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Zwischenprodukte für die Herstellung von kondensierten bicyclischen mTOR-Inhibitoren
CA2641310C (en) * 2006-02-03 2013-08-20 Imclone Systems Incorporated Igf-ir antagonists as adjuvants for treatment of prostate cancer
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
US9340601B2 (en) * 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
WO2008115470A2 (en) * 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
EP2173338A1 (de) * 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Kombinations-antikrebstherapie
EP2178563A2 (de) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Kombinationskrebstherapie mit einem hemmer sowohl für mtorc1 als auch für mtorc2
JP2009055796A (ja) * 2007-08-30 2009-03-19 Shionogi & Co Ltd 延命評価モデル
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
MX2021005168A (es) * 2018-11-02 2021-08-24 Univ Jefferson Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08508405A (ja) * 1993-03-26 1996-09-10 トーマス ジェファーソン ユニバーシティ Ｉｇｆ−１レセプターアンチセンスオリゴヌクレオチドにより細胞の増殖を阻害し、且つ細胞を分化させる方法

Also Published As

Publication number Publication date
DE69719785D1 (de) 2003-04-17
DE69719785T2 (de) 2004-02-05
CA2272824A1 (en) 1998-05-28
EP0941317A1 (de) 1999-09-15
EP0941317B1 (de) 2003-03-12
JP2001504487A (ja) 2001-04-03
WO1998022579A1 (en) 1998-05-28
US6071891A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
ATE234354T1 (de) Zusammensetzung aus brustkrebszellen, die mit einem gegen den rezeptor für insulin-ähnlichen wachstumsfaktor gerichteten antisens- oligonukleotidbehandelt worden sind.
MX9804009A (es) Inhibicion de crecimiento tumoral por oligonucleotidos de antisentido para il-8 y receptor de il-8.
DK1163254T3 (da) TRPM-2 antisense-behandling
ATE294595T1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
EP0796277A4 (de) Reagentien und verfahren zur überexpression von mütierten epidermalen wachstumsfaktorrezeptoren
EP2112167A3 (de) Humanisierte ANTI-ERBB2-Antikörper und Behandlung mit ANTI-ERBB2-Antikörpern
HK1034999A1 (en) Dsrna-mediated regulation of gene expression in plants.
EP1340765A3 (de) Invertierte Chimäre und Hybrid-Oligonukleotide
EP2292771A3 (de) Sense mRNA Therapie
ATE428780T1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
BG106103A (en) Estrogen receptor-beta-ligands
GR20010300033T1 (en) Raf kinase inhibitors
EP0871494A4 (de) Zusammensetzungen und methoden zur behandlung von tumorzellen
AU2001258567A1 (en) Humanised antibodies to the epidermal growth factor receptor
HUP9904359A3 (en) Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules
MX9708401A (es) Genes reguladores de la cromatina.
DE69102903D1 (de) Überzogenes Vitamin-C-Präparat für Tierfutter, dessen Herstellung und Verwendung.
AP2001002104A0 (en) Genes of the 1-desoxy-d-xylulose biosynthetic pathway.
ATE503031T1 (de) Verfahren zur herstellung von sinterkarbidkörpern mit grösserer verschleissfestigkeit
DK1011723T3 (da) 88KDA tumorgen vækstfaktor og antagonister
DE69609725T2 (de) Neue polymerträger zur nukleinsäuresynthese
DE59605323D1 (de) Verfahren zur herstellung von in wasser redispergierbaren, organosiliciumverbindungen enthaltenden pulverzusammensetzungen
EP0943620A3 (de) Betulinsauer Derivate zur Hemmung von Krebswachstum
WO2000032814A3 (en) Methods for producing selected interstrand cross-links in nucleic acids and applications thereof
NO960826L (no) Anvendelse av enzymer fra krill i forstoffer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties